Regulations, liability, safety, and economics related to compounding.
botulinum toxin
compounding
cost
economics
financial
formulation
levigation
lidocaine
regulations
regulatory requirements
safety
Journal
Journal of the American Academy of Dermatology
ISSN: 1097-6787
Titre abrégé: J Am Acad Dermatol
Pays: United States
ID NLM: 7907132
Informations de publication
Date de publication:
Jul 2020
Jul 2020
Historique:
received:
12
09
2019
revised:
26
11
2019
accepted:
26
11
2019
pubmed:
11
12
2019
medline:
22
1
2021
entrez:
11
12
2019
Statut:
ppublish
Résumé
Extemporaneous compounding is a means to tailor a medication to an individual patient's needs and may be required when no commercial product exists to meet that need. Compounded products range from buffered lidocaine to topical creams and ointments. Recent heightened regulations have made compounding more challenging for dermatologists and prompted this review of regulations, liability, and safety related to compounding. With this information, providers may minimize liability and maximize safety while caring for their patients.
Identifiants
pubmed: 31821858
pii: S0190-9622(19)33211-6
doi: 10.1016/j.jaad.2019.11.061
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
184-188Informations de copyright
Copyright © 2019 American Academy of Dermatology, Inc. Published by Elsevier Inc. All rights reserved.